• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

环孢素 A 载固体脂质纳米粒:兔眼的眼内耐受性和体内药物释放。

Cyclosporine a-loaded solid lipid nanoparticles: ocular tolerance and in vivo drug release in rabbit eyes.

机构信息

Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Ege, Izmir, Turkey.

出版信息

Curr Eye Res. 2009 Nov;34(11):996-1003. doi: 10.3109/02713680903261405.

DOI:10.3109/02713680903261405
PMID:19958116
Abstract

PURPOSE

To determine the in vivo efficacy of cyclosporine A-loaded solid lipid nanoparticles (SLNs) in rabbit eyes.

METHODS

SLNs were prepared and administered to the cul-de-sac of rabbits, and the drug amount in aqueous humor was detected by high performance liquid chromatography (HPLC). The irritation was evaluated by modified Draize testing.

RESULTS

The particle size of SLNs was detected as 225.9 +/- 5.5 nm with a negative surface charge. Aqueous humor drug levels reached 50.53 ng/mL, and there was no serious irritation in rabbit eyes.

CONCLUSIONS

Topical ophthalmic efficacy of cyclosporine A was enhanced via administration of SLNs.

摘要

目的

确定环孢素 A 载药固体脂质纳米粒(SLNs)在兔眼内的体内疗效。

方法

将 SLNs 制备并滴入兔眼穹窿部,通过高效液相色谱法(HPLC)检测房水中的药物含量。采用改良 Draize 试验评估刺激性。

结果

SLNs 的粒径检测结果为 225.9±5.5nm,表面带负电荷。房水中的药物水平达到 50.53ng/mL,兔眼未见严重刺激。

结论

通过 SLNs 给药,增强了环孢素 A 的眼部局部疗效。

相似文献

1
Cyclosporine a-loaded solid lipid nanoparticles: ocular tolerance and in vivo drug release in rabbit eyes.环孢素 A 载固体脂质纳米粒:兔眼的眼内耐受性和体内药物释放。
Curr Eye Res. 2009 Nov;34(11):996-1003. doi: 10.3109/02713680903261405.
2
Cyclosporine A loaded SLNs: evaluation of cellular uptake and corneal cytotoxicity.载环孢素A的固体脂质纳米粒:细胞摄取及角膜细胞毒性评估
Int J Pharm. 2008 Nov 19;364(1):76-86. doi: 10.1016/j.ijpharm.2008.07.028. Epub 2008 Aug 3.
3
Cyclosporine-A incorporated cationic solid lipid nanoparticles for ocular delivery.环孢素 A 复合阳离子固体脂质纳米粒经眼部给药。
J Microencapsul. 2010;27(1):37-47. doi: 10.3109/02652040902846883.
4
Development and characterization of Cyclosporine A loaded nanoparticles for ocular drug delivery: Cellular toxicity, uptake, and kinetic studies.环孢素 A 载药纳米粒的制备及眼部给药特性研究:细胞毒性、摄取及动力学研究。
J Control Release. 2011 May 10;151(3):286-94. doi: 10.1016/j.jconrel.2011.01.010. Epub 2011 Jan 15.
5
Injectable actarit-loaded solid lipid nanoparticles as passive targeting therapeutic agents for rheumatoid arthritis.可注射的载有阿他利特的固体脂质纳米粒作为类风湿性关节炎的被动靶向治疗剂
Int J Pharm. 2008 Mar 20;352(1-2):273-9. doi: 10.1016/j.ijpharm.2007.10.014. Epub 2007 Oct 22.
6
Thiolated nanostructured lipid carriers as a potential ocular drug delivery system for cyclosporine A: Improving in vivo ocular distribution.巯基化纳米结构脂质载体作为环孢素 A 的一种潜在眼部药物传递系统:改善体内眼部分布。
Int J Pharm. 2010 Dec 15;402(1-2):248-53. doi: 10.1016/j.ijpharm.2010.10.008. Epub 2010 Oct 8.
7
Preparation of an alternative freeze-dried pH-sensitive cyclosporine A loaded nanoparticles formulation and its pharmacokinetic profile in rats.一种替代的载有pH敏感型环孢素A的冻干纳米颗粒制剂的制备及其在大鼠体内的药代动力学特征。
Pharmazie. 2009 Jan;64(1):26-31.
8
[The pharmacokinetics of FK506 and its nanoparticles in aqueous humor of rabbits].[FK506及其纳米颗粒在兔眼房水中的药代动力学]
Zhonghua Yan Ke Za Zhi. 2006 Apr;42(4):305-8.
9
Topical administration of cyclosporin A in a solid lipid nanoparticle formulation.环孢素A固体脂质纳米粒制剂的局部给药
Pharmazie. 2009 Aug;64(8):510-4.
10
Improvement of digoxin oral absorption in rabbits by incorporation into solid lipid nanoparticles.通过制成固体脂质纳米粒提高家兔对地高辛的口服吸收。
Pharmazie. 2010 Feb;65(2):110-3.

引用本文的文献

1
Assessment of gelatin-epigallocatechin gallate nanoparticles with hyaluronic acid coating for treating dry eye associated keratopathy in rats.评估具有透明质酸涂层的明胶-表没食子儿茶素没食子酸酯纳米颗粒对大鼠干眼症相关性角膜病变的治疗效果。
J Vet Med Sci. 2025 Apr 1;87(4):364-376. doi: 10.1292/jvms.24-0250. Epub 2025 Feb 18.
2
Formulation of Polymeric Nanoparticles Loading Baricitinib as a Topical Approach in Ocular Application.负载巴瑞替尼的聚合物纳米颗粒制剂作为眼部应用的局部给药方法
Pharmaceutics. 2024 Aug 20;16(8):1092. doi: 10.3390/pharmaceutics16081092.
3
Next-generation nanomaterials: advancing ocular anti-inflammatory drug therapy.
下一代纳米材料:推动眼部抗炎药物治疗。
J Nanobiotechnology. 2023 Aug 19;21(1):282. doi: 10.1186/s12951-023-01974-4.
4
Recent Advances of Ocular Drug Delivery Systems: Prominence of Ocular Implants for Chronic Eye Diseases.眼部给药系统的最新进展:眼用植入物在慢性眼病治疗中的突出地位。
Pharmaceutics. 2023 Jun 15;15(6):1746. doi: 10.3390/pharmaceutics15061746.
5
Novel Osmoprotective DOPC-DMPC Liposomes Loaded with Antihypertensive Drugs as Potential Strategy for Glaucoma Treatment.负载抗高血压药物的新型渗透保护型二油酰磷脂酰胆碱-二肉豆蔻酰磷脂酰胆碱脂质体作为青光眼治疗的潜在策略
Pharmaceutics. 2022 Jul 4;14(7):1405. doi: 10.3390/pharmaceutics14071405.
6
Development of α-Tocopherol Succinate-Based Nanostructured Lipid Carriers for Delivery of Paclitaxel.用于紫杉醇递送的基于琥珀酸α-生育酚的纳米结构脂质载体的研发
Pharmaceutics. 2022 May 11;14(5):1034. doi: 10.3390/pharmaceutics14051034.
7
Design of Nanotechnological Carriers for Ocular Delivery of Mangiferin: Preformulation Study.芒果苷眼用纳米载药系统的设计:制剂前研究。
Molecules. 2022 Feb 16;27(4):1328. doi: 10.3390/molecules27041328.
8
Review of Approaches for Increasing Ophthalmic Bioavailability for Eye Drop Formulations.滴眼剂剂型提高眼部生物利用度的方法综述。
AAPS PharmSciTech. 2021 Mar 14;22(3):107. doi: 10.1208/s12249-021-01977-0.
9
Formulation Considerations for the Management of Dry Eye Disease.干眼症管理的制剂考量
Pharmaceutics. 2021 Feb 3;13(2):207. doi: 10.3390/pharmaceutics13020207.
10
Atorvastatin-loaded solid lipid nanoparticles as eye drops: proposed treatment option for age-related macular degeneration (AMD).阿托伐他汀固体脂质纳米粒滴眼剂:治疗年龄相关性黄斑变性(AMD)的新选择。
Drug Deliv Transl Res. 2020 Aug;10(4):919-944. doi: 10.1007/s13346-020-00733-4.